European regulators have approved Eli Lilly's Cyramza (ramucirumab) giving patients with difficult-to-treat stomach cancers a new treatment option.

Specifically, the drug has won clearance to treat patients with advanced stomach or gastro-oesophageal junction adenocarcinoma, after prior chemotherapy with fluoropyrimidine and platinum, and it can be used in combination with paclitaxel or as a single agent.

For more details, go to: http://www.pharmatimes.com/Article/14-12-22/EU_green_light_for_Lilly_s_Cyramza.aspx